Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
114 hedge funds and large institutions have $1.04B invested in Audentes Therapeutics, Inc in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 50 increasing their positions, 16 reducing their positions, and 9 closing their positions.
300% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 9
213% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 16
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
36% more capital invested
Capital invested by funds: $768M → $1.04B (+$274M)
28% more funds holding
Funds holding: 89 → 114 (+25)
12% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $2.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$141M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.1M |
| 3 |
BlackRock
New York
|
+$20.4M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$15.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$20.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.5M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.92M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$4.02M |
BOLD Hedge Fund Activity: Q1 2018 in Review
114 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2018, worth a combined $1.04B — up 36% from $768M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BOLD positions and 9 closed out — a net gain of 27 holders — while 50 added to existing stakes and 16 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $141M. The largest seller was OrbiMed, cutting an estimated $20.6M.
- 114 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2018, up from 89 in Q4 2017.
- Funds reported $1.04B of Audentes Therapeutics, Inc stock for Q1 2018, up 36% quarter-over-quarter.
- 36 funds opened new Audentes Therapeutics, Inc positions in Q1 2018 and 9 closed out, a net change of +27 holders.
- The largest Audentes Therapeutics, Inc buyer in Q1 2018 was Wellington Management Group, an estimated $141M added.
- The largest Audentes Therapeutics, Inc seller in Q1 2018 was OrbiMed, an estimated $20.6M sold.
Based on aggregated 13F filings for Q1 2018.